PF-06865571 for Non-alcoholic Fatty Liver Disease
This trial is testing two new drugs to see if they can improve non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH).
- Non-alcoholic Fatty Liver Disease (NAFLD)
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Side effects dataFrom 2022 Phase 2 trial • 75 Patients • NCT04399538
Find a site
Who is running the clinical trial?
Frequently Asked Questions
Has the regulatory agency cleared PF-06865571 for use?
"Given the Phase 2 state of this drug, there is evidence that it is safe but no indication yet as to its efficacy. Therefore, our team has assigned a score of two out of three in terms of safety."
Does the criteria for entry into this research include individuals aged twenty or younger?
"This study is open to any patients aged 18-75. Patients under the age of 18 can take part in 107 other trials and those over 65 have access to 685 different studies."
Is this medical research recruiting participants at the present time?
"This clinical investigation is not presently recruiting participants, as evident on the information posted in clinicaltrials.gov from June 15th 2020 to November 17th 2022. However, there are currently 766 other medical studies that are looking for volunteers at this exact moment."
Is it possible to become a participant in this experimental investigation?
"To partake in this trial, participants must have fibrosis and range between 18-75 years old. Currently, an estimated 231 persons are taking part."
Are there any research centers carrying out this experiment in North America?
"This medical trial is enrolling a total of 100 patients, some from MUSC Investigational Drug Pharmacy in Charleston, TGH Imaging Powered by Tower Radiology Center (MRI) in Oldsmar and Icahn School of Medicine at Mount Sinai/The Mount Sinai Hospital in New York. There are many other participating clinical sites as well."